Juvena Therapeutics

Juvena Therapeutics

Signal active

Organization

Contact Information

Overview

Juvena Therapeutics is a venture-backed biopharma startup discovering novel protein-based therapeutics that promote tissue regeneration in the elderly and treat various age-related diseases.

About

Industries

Biotechnology, Health Care, Biopharma

Founded

2017

Employees

11-50

Headquarters locations

Palo Alto, California, United States, North America

Social

Profile Resume

Juvena Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Biopharma sector. The company focuses on Biotechnology and has secured $3.5B in funding across 72 round(s). With a team of 11-50 employees, Juvena Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Juvena Therapeutics, raised $41.0M. Discover more about their projects, partnerships, and impact on our platform.

Employees

imagePlace Jeremy O'Connell

Jeremy O'Connell

CSO and Co-Founder

imagePlace Hanadie Yousef

Hanadie Yousef

CEO and Co-Founder

Funding Rounds

Funding rounds

6

Investors

13

Lead Investors

0

Total Funding Amount

$49.2M

Details

3

Juvena Therapeutics has raised a total of $49.2M in funding over 3 rounds.

Announcement dateTransaction nameNumber of InvestorsMoney raisedLead Investor
2018Seed4.3M
2020Seed
2022Early Stage Venture41.0M

Investors

Juvena Therapeutics is funded by 26 investors.

Investor NameLead InvestorFunding RoundPartners
Plum Alley-FUNDING ROUND - Plum Alley41.0M
Intersect VC-FUNDING ROUND - Intersect VC41.0M
Juvena Therapeutics-FUNDING ROUND - Juvena Therapeutics41.0M
Irongrey-FUNDING ROUND - Irongrey41.0M

Recent Activity

News

May 29, 2024

LinkedIn - Hanadie Yousef on LinkedIn: I'll be at BIO 2024 - join me!

News

May 05, 2024

LinkedIn - Kyuho Han on LinkedIn: Pharos iBio and MEDiC to collaborate on new drug research

News

Apr 23, 2024

LinkedIn - Kyuho Han on LinkedIn: Pharos iBio and MEDiC to collaborate on new drug research

News

Apr 04, 2024

LinkedIn - Juvena Therapeutics on LinkedIn: Our CEO, Dr. Hanadie Yousef had a wonderful time at our major investor and…

News

Mar 14, 2024

The Business Journals - How Juvena Therapeutics' CEO found inspiration from family in her fight against chronic illnesses - San Francisco ...

News

Feb 01, 2024

Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy ...